卵巢透明细胞交界性肿瘤临床病理学观察

Ovarian clear cell borderline tumour：a clinicopathologic analysis

目的探讨卵巢透明细胞交界性肿瘤的临床病理学特征及预后。方法收集2011年5月至2017年12月复旦大学附属妇产科医院诊治的12例卵巢透明细胞交界性肿瘤患者的临床病理资料，进行形态学观察和免疫组织化学染色。结果12例患者发病年龄35～65岁，平均52岁。其中7例与卵巢内膜样囊肿有关。所有肿瘤均具有腺纤维瘤背景，腺体扩张，形态不规则拥挤，细胞轻中度异型。所有病例均表达细胞角蛋白7、HNF－1β，11例表达Napsin A。其中5例患者ARID1A失表达。p53均呈野生型表达。随访7～79个月无复发。结论卵巢透明细胞交界性肿瘤可能与子宫内膜异位症及抑癌基因ARID1A相关。随访结果显示无复发和进展为癌的病例，提示预后较好。

ObjectiveTo investigate the clinical and pathological characteristics and prognosis of ovarian clear cell borderline tumor.MethodsA total of 12 cases of ovarian clear cell borderline tumors recorded were collected from May 2011 to December 2017 at Obstetrics and Gynecology Hospital, Fudan University.Clinical histories were retrieved and pathological slides were reviewed.ResultsThe age of the patients ranged from 35 to 65 years with a mean age of 52 years. Seven cases were associated with cystic endometriosis of the ovary. All tumors consisted of irregular and crowded glands or cysts embedded in a fibromatous stroma. The cysts and glands were lined by mild to moderate atypical cells.CK7 and HNF-1β were expressed in all cases, and Naspin A was expressed in 11 cases. ARID1A expression was absent in 5 cases and p53 showed wild-type expression. None of the cases developed recurrence during follow-up ranging from 7 to 79 months.ConclusionsOvarian clear cell borderline tumor may be associated with endometriosis and tumor suppressor gene ARIDA. The tumor has a good prognosis without recurrence and progression to carcinoma.